Mechanisms of the development of androgen independence in prostate cancer.
about
LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancerThe emerging importance of group II PAKsA novel function of caspase-8 in the regulation of androgen-receptor-driven gene expressionOncolytic adenovirus-mediated therapy for prostate cancerProstate cancer relevant antigens and enzymes for targeted drug deliveryParacrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironmentTRPV6 determines the effect of vitamin D3 on prostate cancer cell growthKML001 Induces Apoptosis and Autophagic Cell Death in Prostate Cancer Cells via Oxidative Stress PathwayAtorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independenceEfficacy of c-Met inhibitor for advanced prostate cancer.The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer.Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts.CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling.Riccardin D Exerts Its Antitumor Activity by Inducing DNA Damage in PC-3 Prostate Cancer Cells In Vitro and In Vivo.Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer.Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP modelThe Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate CancerThe inhibitory effects of AR/miR-190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism.Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCĪµ, Stat3 and neuroendocrine markersThe potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer.PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer.New players for advanced prostate cancer and the rationalisation of insulin-sensitising medicationMagnetic nanoparticles of Fe3O4 enhance docetaxel-induced prostate cancer cell death.Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.Emerging biological observations in prostate cancer.IGF-I, insulin and prostate cancer.Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.Abiraterone acetate for castration resistant prostate cancer.Cholesterol as a potential target for castration-resistant prostate cancer.Cabazitaxel for the treatment of prostate cancer.Tumor cell-selective apoptosis induction through targeting of K(V)10.1 via bifunctional TRAIL antibody.Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting.Induction of DNA damage and p21-dependent senescence by Riccardin D is a novel mechanism contributing to its growth suppression in prostate cancer cells in vitro and in vivo.Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3M-luciferase cells in an orthotopic xenograft mouse model.Inhibition of progression of androgen-dependent prostate LNCaP tumors to androgen independence in SCID mice by oral caffeine and voluntary exercise.Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.Bone-metastatic prostate carcinoma favors mesenchymal stem cell differentiation toward osteoblasts and reduces their osteoclastogenic potential.Structural and functional analysis of amino-terminal enhancer of split in androgen-receptor-driven transcription.Action mechanism and signal pathways of Psidium guajava L. aqueous extract in killing prostate cancer LNCaP cells.
P2860
Q21202034-9133469F-D0B5-47C7-878C-8062353A9879Q24294885-FAD2C731-54AF-4741-86D5-4A0CA98733A2Q24336995-6BB3453B-3448-4242-B264-8E860618FB4BQ27004796-834A93EA-BC25-40E8-AF7D-2D372E0603A0Q27013843-CEFC3965-6999-4C86-A1C3-B01F5A904EC7Q28278828-F7D534FB-4E3F-464D-A704-4DDF22838C5DQ28477138-6C4A0F02-C475-428C-BFFF-633C2321837EQ28547789-16F0CC80-0FFA-4196-A4CE-CBA64B134411Q33579568-3E75760F-52B4-40B7-9F6D-13C50EB4C2CAQ33718726-8DE96B0D-CC77-4585-A5DF-89FE01F7DA60Q33976977-F48872F8-9266-408A-8233-0CC760D737C5Q34383988-7CEF0485-4FEA-4F8A-AEC1-C63CCC709F9FQ34786431-36DDDA5E-C879-4FDF-AF8E-B335B227B7AEQ34999154-DB707BD1-D61C-4EFA-95DC-E9E2386F7489Q35146525-0CD2DA99-7F85-4578-833D-DABC91C1613EQ35597031-8A229EF3-BC32-4645-9D78-5309B3D07682Q35882782-CB00C6EF-4D65-4520-9DBD-F416B354863DQ36002634-A572C5B6-0E28-478F-9618-38A3B7C791B1Q36381291-D40B8175-F839-422B-B691-A63D61E2CA0DQ36435787-15E027F2-D0D2-4AD5-B9C7-D0C97C152149Q36458374-48CF1596-51EF-48D7-B470-2098A5F21FF9Q36567984-B194BC5D-604F-482F-A115-B07436936C27Q36734036-08C36697-B2A2-4660-ACEF-49F5E84AEB5BQ37120640-1BFB89CC-7A9A-4C91-A769-B8257FDB03CCQ37424118-E3049633-EC2B-48A1-A277-B949CF32A8CBQ37656229-4F3E09E6-9FA8-40C0-B60D-5939F3268116Q37686154-6862011C-FF62-4D6F-B2B3-C10CD167F3FDQ37694029-5A0C7306-6EBA-4623-A88A-8AE47997E27FQ37708308-D8A84BAC-93B9-4E5B-B91F-7E5D68AD6BE8Q37777663-1F5093DE-8CD4-499F-B288-45B6C72FEF00Q37853193-9918A142-DDFC-48EE-894A-EA24A4D81F3BQ38554434-3D43EAC6-A484-455A-84C7-DB02FB964BECQ39016653-DA4A349B-8DE6-4DF8-97FF-EAFC2FF4056FQ39045060-BD14DBD9-F120-4B34-B0E9-EE791BA984F6Q39219294-F04D9B74-2C4C-476C-AC45-C5551846F9EFQ39260494-6070603B-8B0C-434F-9916-59695EC40A05Q39398599-F58081F5-904F-4D89-9975-060C16F6AE26Q39456241-9A25F4B6-198A-401B-9244-B7FEC2496FE1Q39738255-095D238D-62C7-4B8C-AC6B-0A33F2E3CBDCQ39748389-BF20472E-E76F-48FD-A8C7-12846BFDCA2A
P2860
Mechanisms of the development of androgen independence in prostate cancer.
description
2005 nĆ® lÅ«n-bĆ»n
@nan
2005幓ć®č«ę
@ja
2005幓č«ę
@yue
2005幓č«ę
@zh-hant
2005幓č«ę
@zh-hk
2005幓č«ę
@zh-mo
2005幓č«ę
@zh-tw
2005幓č®ŗę
@wuu
2005幓č®ŗę
@zh
2005幓č®ŗę
@zh-cn
name
Mechanisms of the development of androgen independence in prostate cancer.
@ast
Mechanisms of the development of androgen independence in prostate cancer.
@en
type
label
Mechanisms of the development of androgen independence in prostate cancer.
@ast
Mechanisms of the development of androgen independence in prostate cancer.
@en
prefLabel
Mechanisms of the development of androgen independence in prostate cancer.
@ast
Mechanisms of the development of androgen independence in prostate cancer.
@en
P2093
P1476
Mechanisms of the development of androgen independence in prostate cancer.
@en
P2093
Antonio Hurtado-Col
Colleen Nelson
Martin Gleave
P2888
P356
10.1007/S00345-004-0473-1
P577
2005-01-27T00:00:00Z